4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

F. Cardoso; E. Senkus; A. Costa; E. Papadopoulos; M. Aapro; F. André; N. Harbeck; B. Aguilar Lopez; C. H. Barrios; J. Bergh; L. Biganzoli; C. B. Boers-Doets; M. J. Cardoso; L. A. Carey; J. Cortés; G. Curigliano; V. Dié Ras; N. S. El Saghir; A. Eniu; L. Fallowfield; P. A. Francis; K. Gelmon; S. R.D. Johnston; B. Kaufman; S. Koppikar; I. E. Krop; M. Mayer; G. Nakigudde; B. V. Offersen; S. Ohno; O. Pagani; S. Paluch-Shimon; F. Penault-Llorca; A. Prat; H. S. Rugo; G. W. Sledge; D. Spence; C. Thomssen; D. A. Vorobiof; B. Xu; L. Norton; E. P. Winer

doi:10.1093/annonc/mdy192

4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

F. Cardoso
, E. Senkus
, A. Costa
, E. Papadopoulos
, M. Aapro
, F. André
, N. Harbeck
, B. Aguilar Lopez
, C. H. Barrios
, J. Bergh
, L. Biganzoli
, C. B. Boers-Doets
, M. J. Cardoso
, L. A. Carey
, J. Cortés
, G. Curigliano
, V. Dié Ras
, N. S. El Saghir
, A. Eniu
, L. Fallowfield

P. A. Francis, K. Gelmon, S. R.D. Johnston, B. Kaufman, S. Koppikar, I. E. Krop, M. Mayer, G. Nakigudde, B. V. Offersen, S. Ohno, O. Pagani, S. Paluch-Shimon, F. Penault-Llorca, A. Prat, H. S. Rugo, G. W. Sledge, D. Spence, C. Thomssen, D. A. Vorobiof, B. Xu, L. Norton, E. P. Winer

Health Science Center

Champalimaud Clinical Center
Medical University of Gdańsk
European School of Oncology
Europa Donna Cyprus
Clinique de Genolier
Institut Gustave Roussy
Ludwig Maximilian University of Munich
Direction Office
PURCS School of Medicine
Karolinska Institutet
Nuovo Ospedale di Prato – Istituto Toscano Tumori
CB Boers Organization
University of North Carolina at Chapel Hill
Hosp Valle De Hebron
University of Milan
Centre Georges-François Leclerc
American University of Beirut
Cancer Institute Prof Dr Ion Chiricuta
University of Sussex
Peter Maccallum Cancer Centre
Provincial Health Services Authority
Royal Marsden
Sheba Medical Center at Tel Hashomer
Bombay Hospital and Medical Research Centre
Dana-Farber Cancer Institute
AdvancedBC.org
UWOCASO (Uganda Women's Cancer Support Organization)
Aarhus University
Japanese Foundation for Cancer Research
University of Geneva
Shaare Zedek Medical Center
Centre Jean Perrin
Hospital Clinic
University of California at San Francisco
Stanford University
Breast Cancer Network Australia
Martin Luther University Halle-Wittenberg
Sandton Oncology Centre
Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

1015 Scopus citations

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

Original language	English
Pages (from-to)	1634-1657
Number of pages	24
Journal	Annals of Oncology
Volume	29
Issue number	8
DOIs	https://doi.org/10.1093/annonc/mdy192
State	Published - Aug 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ABC
Advanced
Breast cancer
ESO-ESMO
Guidelines
Metastatic

Access to Document

10.1093/annonc/mdy192

Cite this

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B., Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Dié Ras, V., El Saghir, N. S., Eniu, A., ... Winer, E. P. (2018). 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Annals of Oncology, 29(8), 1634-1657. https://doi.org/10.1093/annonc/mdy192

@article{bbeacc0ddbca44728e18b1ebb77694ce,

title = "4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)",

abstract = "Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25\% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].",

keywords = "ABC, Advanced, Breast cancer, ESO-ESMO, Guidelines, Metastatic",

author = "F. Cardoso and E. Senkus and A. Costa and E. Papadopoulos and M. Aapro and F. Andr{\'e} and N. Harbeck and \{Aguilar Lopez\}, B. and Barrios, \{C. H.\} and J. Bergh and L. Biganzoli and Boers-Doets, \{C. B.\} and Cardoso, \{M. J.\} and Carey, \{L. A.\} and J. Cort{\'e}s and G. Curigliano and \{Di{\'e} Ras\}, V. and \{El Saghir\}, \{N. S.\} and A. Eniu and L. Fallowfield and Francis, \{P. A.\} and K. Gelmon and Johnston, \{S. R.D.\} and B. Kaufman and S. Koppikar and Krop, \{I. E.\} and M. Mayer and G. Nakigudde and Offersen, \{B. V.\} and S. Ohno and O. Pagani and S. Paluch-Shimon and F. Penault-Llorca and A. Prat and Rugo, \{H. S.\} and Sledge, \{G. W.\} and D. Spence and C. Thomssen and Vorobiof, \{D. A.\} and B. Xu and L. Norton and Winer, \{E. P.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.",

year = "2018",

month = aug,

doi = "10.1093/annonc/mdy192",

language = "英语",

volume = "29",

pages = "1634--1657",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "8",

}

Cardoso, F, Senkus, E, Costa, A, Papadopoulos, E, Aapro, M, André, F, Harbeck, N, Aguilar Lopez, B, Barrios, CH, Bergh, J, Biganzoli, L, Boers-Doets, CB, Cardoso, MJ, Carey, LA, Cortés, J, Curigliano, G, Dié Ras, V, El Saghir, NS, Eniu, A, Fallowfield, L, Francis, PA, Gelmon, K, Johnston, SRD, Kaufman, B, Koppikar, S, Krop, IE, Mayer, M, Nakigudde, G, Offersen, BV, Ohno, S, Pagani, O, Paluch-Shimon, S, Penault-Llorca, F, Prat, A, Rugo, HS, Sledge, GW, Spence, D, Thomssen, C, Vorobiof, DA, Xu, B, Norton, L & Winer, EP 2018, '4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)', Annals of Oncology, vol. 29, no. 8, pp. 1634-1657. https://doi.org/10.1093/annonc/mdy192

TY - JOUR

T1 - 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

AU - Cardoso, F.

AU - Senkus, E.

AU - Costa, A.

AU - Papadopoulos, E.

AU - Aapro, M.

AU - André, F.

AU - Harbeck, N.

AU - Aguilar Lopez, B.

AU - Barrios, C. H.

AU - Bergh, J.

AU - Biganzoli, L.

AU - Boers-Doets, C. B.

AU - Cardoso, M. J.

AU - Carey, L. A.

AU - Cortés, J.

AU - Curigliano, G.

AU - Dié Ras, V.

AU - El Saghir, N. S.

AU - Eniu, A.

AU - Fallowfield, L.

AU - Francis, P. A.

AU - Gelmon, K.

AU - Johnston, S. R.D.

AU - Kaufman, B.

AU - Koppikar, S.

AU - Krop, I. E.

AU - Mayer, M.

AU - Nakigudde, G.

AU - Offersen, B. V.

AU - Ohno, S.

AU - Pagani, O.

AU - Paluch-Shimon, S.

AU - Penault-Llorca, F.

AU - Prat, A.

AU - Rugo, H. S.

AU - Sledge, G. W.

AU - Spence, D.

AU - Thomssen, C.

AU - Vorobiof, D. A.

AU - Xu, B.

AU - Norton, L.

AU - Winer, E. P.

PY - 2018/8

Y1 - 2018/8

N2 - Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

AB - Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

KW - ABC

KW - Advanced

KW - Breast cancer

KW - ESO-ESMO

KW - Guidelines

KW - Metastatic

UR - https://www.scopus.com/pages/publications/85053909898

U2 - 10.1093/annonc/mdy192

DO - 10.1093/annonc/mdy192

M3 - 文章

C2 - 30032243

AN - SCOPUS:85053909898

SN - 0923-7534

VL - 29

SP - 1634

EP - 1657

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this